NCT01760694

Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Southwestern Regional Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To assess the ability of a combination of updated and approved modalities in the treatment of first line pancreatic cancer patients to increase the time to Progression Free Survival

Detailed description

For resectable patient; surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery. For marginally resectable patients; the patients will have 2-3 cycles of neoadjuvant chemotherapy of FOLFIRINOX and then restaged, undergo surgery with IORT within 2-4 weeks following chemotherapy. Then radiation therapy starting within 6-8 weeks. Followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
OTHER	Multi-Modality; IORT, Surgery, Radiation, Chemotherapy

Timeline

• Start date: 2013-01-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2013-01-04
• Last updated: 2014-08-15

Locations

1 site across 1 country: United States